Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims

Lab Test Company Did Not Conduct Data Analysis

 
• By Andrew McConaghie

Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.

Cassava Sciences
Cassava has seen its share price dive as the claims behind its small molecule therapy come under increasing scrutiny.

More from Business

More from Scrip